Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Ovarian Neoplasms 16Fallopian Tube Neoplasms 14Sarcoma 5Breast Neoplasms 5Carcinoma, Ovarian Epithelial 4Neoplasms 3Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Sarcoma, Ewing 2Multi-centric Castleman's Disease 2Hodgkin Disease 2Vulvar Neoplasms 1Vaginal Neoplasms 1Vaccinia 1Uterine Cervical Neoplasms 1Sarcoma, Synovial 1Sarcoma, Kaposi 1Rhabdomyosarcoma 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma 1Recurrence 1Peritoneal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Cancer Recurrent 1Osteosarcoma 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphadenopathy 1

Interventions

Specimen Handling 4Magnetic Resonance Spectroscopy 4Doxorubicin 4pembrolizumab 3Radiotherapy 3Radiation 3Biopsy 3pazopanib 2palbociclib 2abemaciclib 2Immunoglobulin G 2Ifosfamide 2toripalimab 1talimogene laherparepvec 1silmitasertib 1selinexor 1ribociclib 1peposertib 1mirdametinib 1liposomal doxorubicin 1eribulin 1durvalumab 1cemiplimab 1X-Rays 1Vincristine 1Temozolomide 1Surgical Procedures, Operative 1Radiotherapy, Intensity-Modulated 1Proton Therapy 1Neoadjuvant Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liposarcoma × liposomal doxorubicin × 90 days × Clear all
NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡